U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H15Cl2N2O2P
Molecular Weight 261.0861
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYCLOPHOSPHAMIDE ANHYDROUS

SMILES

C1CNP(=O)(N(CCCl)CCCl)OC1

InChI

InChIKey=CMSMOCZEIVJLDB-UHFFFAOYSA-N
InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)

HIDE SMILES / InChI
Cyclophosphamide (the generic name for Cytoxan, Neosar, Revimmune), also known as cytophosphane, is a nitrogen mustard alkylating agent, from the oxazophorines group. It is used to treat various types of cancer and some autoimmune disorders. It is a "prodrug"; it is converted in the liver to active forms that have chemotherapeutic activity

Originator

Curator's Comment:: Cyclophosphamide was developed by Norbert Brock and ASTA (now Baxter Oncology).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1234 μg/L
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: Imatinib | Bevacizumab
CYCLOPHOSPHAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
17587 μg × h/L
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: Imatinib | Bevacizumab
CYCLOPHOSPHAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.8 h
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: Imatinib | Bevacizumab
CYCLOPHOSPHAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
CYCLOPHOSPHAMIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg/m2 2 times / day multiple, intravenous
MTD
Dose: 200 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 5
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 5
Sources: Page: p.5, 16
Other AEs: Bilirubin total increased, Diarrhea...
Other AEs:
Bilirubin total increased (grade 3, 20%)
Diarrhea (grade 3, 20%)
Sources: Page: p.5, 16
300 mg/m2 2 times / day multiple, intravenous
Studied dose
Dose: 300 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 25
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 25
Sources: Page: p.5, 16
DLT: Diarrhea, Lipase increased...
Dose limiting toxicities:
Diarrhea (grade 3-5, 12%)
Lipase increased (grade 4, 4%)
Transaminases increased (grade 3-5, 12%)
Nausea and vomiting (grade 3-5, 4%)
Sources: Page: p.5, 16
3300 mg/m2 single, intravenous
Highest studied dose
Dose: 3300 mg/m2
Route: intravenous
Route: single
Dose: 3300 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
DLT: Neutropenia, Thrombocytopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 33.3%)
Thrombocytopenia (16.7%)
Neutropenia (16.7%)
Sources: Page: p.98
2700 mg/m2 single, intravenous
MTD
Dose: 2700 mg/m2
Route: intravenous
Route: single
Dose: 2700 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
DLT: Neutropenia, Thrombocytopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 16.7%)
Thrombocytopenia (16.7%)
Neutropenia (16.7%)
Sources: Page: p.98
2000 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2000 mg/m2, 1 times / 3 weeks
Co-administed with::
paclitaxel, i.v(200 mg/m2, once in 3 weeks, 5 cycles)
Sources: Page: p.658
unhealthy, 27 - 70
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 27 - 70
Sex: F
Population Size: 6
Sources: Page: p.658
DLT: Febrile neutropenia, Thrombocytopenia...
Dose limiting toxicities:
Febrile neutropenia (33.3%)
Thrombocytopenia (grade 4, 16.7%)
Sources: Page: p.658
100 mg 1 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
paclitaxel, i.v(175 mg/m(2) (Day 1), 6 cycles)
Sources: Page: p.519
unhealthy, 47-78
n = 6
Health Status: unhealthy
Condition: Urothelial bladder cancer
Age Group: 47-78
Sex: M+F
Population Size: 6
Sources: Page: p.519
DLT: Neutropenia, Thrombocytopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 33.3%)
Thrombocytopenia (grade 4, 16.7%)
Constipation (grade 3, 16.7%)
Sources: Page: p.519
50 mg 1 times / day multiple, oral
MTD
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
paclitaxel, i.v(175 mg/m(2) (Day 1), 12 cycles)
Sources: Page: p.519
unhealthy, 47-78
n = 6
Health Status: unhealthy
Condition: Urothelial bladder cancer
Age Group: 47-78
Sex: M+F
Population Size: 6
Sources: Page: p.519
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Disc. AE: Myelosuppression, Immunosuppression...
AEs leading to
discontinuation/dose reduction:
Myelosuppression
Immunosuppression
Bone marrow failure
Infection
Urinary tract toxicity
Toxicity renal
Cystitis hemorrhagic
Pyelitis
Ureteritis
Hematuria
Cardiotoxicity
Myocarditis
Myopericarditis
Pericardial effusion
Arrhythmia (NOS)
Congestive heart failure
Pulmonary toxicity
Pneumonitis
Pulmonary fibrosis
Pulmonary veno-occlusive disease
Respiratory failure
Metastases
Venoocclusive liver disease
Fetal damage
Sources: Page: p.1
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Disc. AE: Myelosuppression, Immunosuppression...
AEs leading to
discontinuation/dose reduction:
Myelosuppression
Immunosuppression
Bone marrow failure
Infection
Urinary tract toxicity
Toxicity renal
Cystitis hemorrhagic
Pyelitis
Ureteritis
Hematuria
Cardiotoxicity
Myocarditis
Myopericarditis
Pericardial effusion
Arrhythmia (NOS)
Congestive heart failure
Pulmonary toxicity
Pneumonitis
Pulmonary fibrosis
Pulmonary veno-occlusive disease
Respiratory failure
Metastases
Venoocclusive liver disease
Fetal damage
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Bilirubin total increased grade 3, 20%
200 mg/m2 2 times / day multiple, intravenous
MTD
Dose: 200 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 5
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 5
Sources: Page: p.5, 16
Diarrhea grade 3, 20%
200 mg/m2 2 times / day multiple, intravenous
MTD
Dose: 200 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 5
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 5
Sources: Page: p.5, 16
Diarrhea grade 3-5, 12%
DLT
300 mg/m2 2 times / day multiple, intravenous
Studied dose
Dose: 300 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 25
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 25
Sources: Page: p.5, 16
Transaminases increased grade 3-5, 12%
DLT
300 mg/m2 2 times / day multiple, intravenous
Studied dose
Dose: 300 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 25
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 25
Sources: Page: p.5, 16
Nausea and vomiting grade 3-5, 4%
DLT
300 mg/m2 2 times / day multiple, intravenous
Studied dose
Dose: 300 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 25
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 25
Sources: Page: p.5, 16
Lipase increased grade 4, 4%
DLT
300 mg/m2 2 times / day multiple, intravenous
Studied dose
Dose: 300 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 25
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 25
Sources: Page: p.5, 16
Neutropenia 16.7%
DLT
3300 mg/m2 single, intravenous
Highest studied dose
Dose: 3300 mg/m2
Route: intravenous
Route: single
Dose: 3300 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Thrombocytopenia 16.7%
DLT
3300 mg/m2 single, intravenous
Highest studied dose
Dose: 3300 mg/m2
Route: intravenous
Route: single
Dose: 3300 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Neutropenia grade 4, 33.3%
DLT
3300 mg/m2 single, intravenous
Highest studied dose
Dose: 3300 mg/m2
Route: intravenous
Route: single
Dose: 3300 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Neutropenia 16.7%
DLT
2700 mg/m2 single, intravenous
MTD
Dose: 2700 mg/m2
Route: intravenous
Route: single
Dose: 2700 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Thrombocytopenia 16.7%
DLT
2700 mg/m2 single, intravenous
MTD
Dose: 2700 mg/m2
Route: intravenous
Route: single
Dose: 2700 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Neutropenia grade 4, 16.7%
DLT
2700 mg/m2 single, intravenous
MTD
Dose: 2700 mg/m2
Route: intravenous
Route: single
Dose: 2700 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Febrile neutropenia 33.3%
DLT
2000 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2000 mg/m2, 1 times / 3 weeks
Co-administed with::
paclitaxel, i.v(200 mg/m2, once in 3 weeks, 5 cycles)
Sources: Page: p.658
unhealthy, 27 - 70
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 27 - 70
Sex: F
Population Size: 6
Sources: Page: p.658
Thrombocytopenia grade 4, 16.7%
DLT
2000 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2000 mg/m2, 1 times / 3 weeks
Co-administed with::
paclitaxel, i.v(200 mg/m2, once in 3 weeks, 5 cycles)
Sources: Page: p.658
unhealthy, 27 - 70
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 27 - 70
Sex: F
Population Size: 6
Sources: Page: p.658
Constipation grade 3, 16.7%
DLT
100 mg 1 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
paclitaxel, i.v(175 mg/m(2) (Day 1), 6 cycles)
Sources: Page: p.519
unhealthy, 47-78
n = 6
Health Status: unhealthy
Condition: Urothelial bladder cancer
Age Group: 47-78
Sex: M+F
Population Size: 6
Sources: Page: p.519
Thrombocytopenia grade 4, 16.7%
DLT
100 mg 1 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
paclitaxel, i.v(175 mg/m(2) (Day 1), 6 cycles)
Sources: Page: p.519
unhealthy, 47-78
n = 6
Health Status: unhealthy
Condition: Urothelial bladder cancer
Age Group: 47-78
Sex: M+F
Population Size: 6
Sources: Page: p.519
Neutropenia grade 4, 33.3%
DLT
100 mg 1 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
paclitaxel, i.v(175 mg/m(2) (Day 1), 6 cycles)
Sources: Page: p.519
unhealthy, 47-78
n = 6
Health Status: unhealthy
Condition: Urothelial bladder cancer
Age Group: 47-78
Sex: M+F
Population Size: 6
Sources: Page: p.519
Arrhythmia (NOS) Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Bone marrow failure Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Cardiotoxicity Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Congestive heart failure Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Cystitis hemorrhagic Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Fetal damage Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Hematuria Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Immunosuppression Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Infection Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Metastases Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myelosuppression Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myocarditis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myopericarditis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pericardial effusion Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pneumonitis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary fibrosis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary toxicity Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary veno-occlusive disease Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pyelitis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Respiratory failure Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Toxicity renal Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Ureteritis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Urinary tract toxicity Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Venoocclusive liver disease Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Arrhythmia (NOS) Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Bone marrow failure Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Cardiotoxicity Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Congestive heart failure Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Cystitis hemorrhagic Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Fetal damage Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Hematuria Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Immunosuppression Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Infection Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Metastases Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myelosuppression Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myocarditis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myopericarditis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pericardial effusion Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pneumonitis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary fibrosis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary toxicity Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary veno-occlusive disease Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pyelitis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Respiratory failure Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Toxicity renal Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Ureteritis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Urinary tract toxicity Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Venoocclusive liver disease Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
weak (co-administration study)
Comment: coadministration with ketoconazole: had small effect on CYCLOPHOSPHAMIDE plasma concentration
Page: 15.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes (co-administration study)
Comment: coadministration with ketoconazole: caused a KTZ dose-dependent decrease in main parameters of DECP (Cmax, Tmax, and AUC0–∞) and provided magnitude exposure of DECP (more than a 50% AUC decrease) as a consequence of CYP3A inhibition
PubMed

PubMed

TitleDatePubMed
Carcinoma of the urinary bladder in patients receiving cyclophosphamide.
1975 Aug 7
Remission of active chronic hepatitis after treatment with cyclophosphamide and prednisolone. Report of four cases.
1975 Feb
[Apoptosis of B lymphocytic leukemia induced by anticancer drugs and their cell cycle specificity].
1998 Jan
Deficits in visceral pain and hyperalgesia of mice with a disruption of the tachykinin NK1 receptor gene.
2000
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
2000 Apr 1
Limits to the "benefits" from our oncologic interventions: a case report.
2000 Aug
GST-pi gene-transduced hematopoietic progenitor cell transplantation overcomes the bone marrow toxicity of cyclophosphamide in mice.
2000 Aug 10
Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
2000 Dec 15
Studies on the anti-inflammatory and related pharmacological properties of the aqueous extract of Bridelia ferruginea stem bark.
2000 Jul
Ruptured Klebsiella pneumoniae liver abscess after high-dose cyclophosphamide for severe aplastic anemia.
2000 Jul
Paternal exposure to cyclophosphamide alters cell-cell contacts and activation of embryonic transcription in the preimplantation rat embryo.
2000 Jul
Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.
2000 Jul
Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
2000 Jul 15
Invasive bladder cancer after cyclophosphamide administration for nephrotic syndrome--a case report.
2000 Jun
Cyclophosphamide and water retention: mechanism revisited.
2000 Jun
[Cyclophosphamide-induced renal pelvic tumor--a case report].
2000 Mar
QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide.
2000 Mar 4
Dramatic aneurysm regression in polyarteritis nodosa following high dose pulse cyclophosphamide.
2000 May
Up-regulation of pituitary adenylate cyclase-activating polypeptide in urinary bladder pathways after chronic cystitis.
2000 May 8
[Assessment of cardiotoxicity of high dose cyclophosphamide with electrocardiographic, echocardiographic, and troponin I monitoring in patients with breast tumors].
2000 Nov
Nitric oxide and NK(1)-tachykinin receptors in cyclophosphamide-induced cystitis, in rats.
2000 Nov
Paternal exposure to cyclophosphamide induces DNA damage and alters the expression of DNA repair genes in the rat preimplantation embryo.
2000 Nov 9
Report of severe neurotoxicity with cyclophosphamide.
2000 Nov-Dec
Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.
2000 Oct
Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect.
2000 Oct
Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure.
2000 Sep
Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy.
2000 Sep
Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience.
2001
Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
2001 Aug
Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide.
2001 Aug
Transient posterior encephalopathy induced by chemotherapy in children.
2001 Feb
Azathioprine-induced destructive cholangitis.
2001 Feb
Cyclophosphamide-induced hemorrhagic cystitis in rats that underwent colocystoplasty: experimental study.
2001 Feb
Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector.
2001 Feb 1
Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.
2001 Feb 15
Involvement of hypogastric and pelvic nerves for conveying cystitis induced nociception in conscious rats.
2001 Jul
Bladder carcinoma associated with cyclophosphamide therapy for ovarian cancer occurring with a latency of 20 years.
2001 Jul
Leiomyosarcoma of the bladder fourteen years after cyclophosphamide therapy for retinoblastoma.
2001 Jun
Transitional cell carcinoma of the urinary bladder following exposure to cyclophosphamide in childhood.
2001 Jun
Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology.
2001 Jun
Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
2001 Jun 1
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome.
2001 Jun 15
Treatment based on a combination of the CYP2B1/cyclophosphamide system and p53 delivery enhances tumour regression in human pancreatic cancer.
2001 Mar
Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose.
2001 Mar
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
2001 Mar 1
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
2001 Mar 15
Contribution of alveolar phagocytes to antibiotic efficacy in an experimental lung infection with Streptococcus pneumoniae.
2001 May
Protective effect of berberine on cyclophosphamide-induced haemorrhagic cystitis in rats.
2001 May
Dominant role of intercellular adhesion molecule-1 in the pathogenesis of autoimmune diabetes in non-obese diabetic mice.
2001 Sep
Prevention of further cyclophosphamide induced hemorrhagic cystitis by hyperbaric oxygen and mesna in guinea pigs.
2001 Sep
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Cyclophosphamide can also be administered orally (1 mg per kg per day to 5 mg per kg per day) in malignant diseases.
40-50 mg per kg in divided doses over 2 to 5 days in malignant diseases and 2 mg per kg daily for 8 to 12 weeks in minimal change nephrotic sindrome
Route of Administration: Intravenous
In Vitro Use Guide
Curator's Comment:: Cyclophosphamide was tested for its ability to inhibit human lymphocyte proliferation and to modulate lymphocyte response to mitogens in vitro. At higher concentrations (20 to 160 ug/ml), the drug had a suppressive effect with a maximum suppression of 99%.
from 20 to 160 ug/ml
Name Type Language
CYCLOPHOSPHAMIDE ANHYDROUS
Common Name English
NSC-26271
Code English
ANHYDROUS CYCLOPHOSPHAMIDE
Common Name English
(+/-)-2-(BIS(2-CHLOROETHYL)AMINO)TETRAHYDRO-2H-1,3,2-OXAZAPHOSPHORINE 2-OXIDE
Systematic Name English
2H-1,3,2-OXAZAPHOSPHORIN-2-AMINE, N,N-BIS(2-CHLOROETHYL)TETRAHYDRO-, 2-OXIDE
Systematic Name English
CYCLOPHOSPHAMIDE [HSDB]
Common Name English
CYCLOPHOSPHAMIDE [WHO-DD]
Common Name English
CYCLOPHOSPHAMIDE LYOPHILIZED
Common Name English
CYCLOPHOSPHAMIDE ANHYDROUS [MI]
Common Name English
CYCLOPHOSPHAMIDE [INN]
Common Name English
CYCLOPHOSPHAMIDE, ANHYDROUS
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C697
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
NDF-RT N0000000236
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
EPA PESTICIDE CODE 624870
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
NDF-RT N0000175558
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
WHO-ATC L01AA01
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
NCI_THESAURUS C574
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
Code System Code Type Description
HSDB
3047
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
CAS
50-18-0
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
FDA UNII
6UXW23996M
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
EVMPD
SUB121739
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
PUBCHEM
2907
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
RXCUI
221085
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
ALTERNATIVE
EVMPD
SUB06859MIG
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
INN
878
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
DRUG BANK
DB00531
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
MERCK INDEX
M4013
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY Merck Index
EPA CompTox
50-18-0
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-015-4
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
RXCUI
1545988
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
NCI_THESAURUS
C61694
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY